Sermorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) consisting of the first 29 amino acids of the endogenous 44-amino acid GHRH sequence. As the biologically active N-terminal fragment of GHRH, Sermorelin retains full receptor-binding activity at the GHRH receptor while offering a shorter, more stable peptide for research applications. It was previously FDA-approved under the brand name Geref for the diagnosis and treatment of pediatric growth hormone deficiency — a regulatory history that provides an extensive clinical data set to complement its ongoing preclinical research applications.
For researchers examining the GHRH-GH-IGF-1 endocrine axis, growth hormone secretion dynamics, or age-related endocrine changes, Sermorelin represents a well-characterized, extensively studied tool compound with decades of published literature in both animal models and human subjects.
Sermorelin (GHRH 1-29 amide) is a truncated analogue of human growth hormone-releasing hormone, comprising residues 1 through 29 of the mature GHRH sequence with an amidated C-terminus. Biochemical studies established that the first 29 amino acids of GHRH are sufficient for full biological activity at the GHRH receptor — the additional residues in full-length GHRH (residues 30-44) contribute to stability but not to receptor binding affinity or activation.
Sermorelin acts as a direct agonist of the GHRH receptor (GHRHR), a G-protein-coupled receptor expressed on somatotroph cells in the anterior pituitary. Receptor activation stimulates adenylyl cyclase, increases intracellular cAMP, and promotes both GH gene transcription and GH secretion. Unlike GH receptor agonists, Sermorelin preserves the physiological pulsatile pattern of GH release by working through the body’s normal secretory machinery rather than bypassing it.
The compound is supplied as a white lyophilized powder and reconstitutes readily in sterile bacteriostatic water. Its relatively short half-life of 10-20 minutes in plasma makes Sermorelin suitable for research designs examining acute GH pulse stimulation, and it is frequently compared to longer-acting GHRH analogues such as CJC-1295 DAC in comparative pharmacokinetic research.
| Property | Value |
|---|---|
| Full name | Sermorelin acetate (GHRH 1-29-NH₂) |
| Also known as | GRF 1-29, Somatocrinin 1-29, Geref |
| Molecular formula | C₁₄₉H₂₄₆N₄₄O₄₂S |
| Molecular weight | 3,357.93 g/mol |
| CAS number | 86168-78-7 |
| Purity (Official Peptides) | >99% by HPLC |
| Physical form | White lyophilized powder |
| Solubility | Water soluble |
| Half-life (plasma) | ~10–20 minutes |
| Storage (lyophilized) | 2–8°C, protected from light |
| Storage (reconstituted) | 4°C, use within 30 days |
Sermorelin’s most fundamental research application involves its use as a GHRH receptor agonist for stimulating and studying GH secretion. Its well-defined receptor pharmacology — full agonism at GHRHR with no known activity at other receptor systems — makes it a clean pharmacological tool for isolating GHRH-pathway effects in experimental GH axis research.
Research has characterized Sermorelin’s dose-response relationship for GH secretion across species, documenting the relationship between Sermorelin administration timing, endogenous somatostatin tone, and GH pulse amplitude. Studies have established that Sermorelin’s GH-stimulating effect is potentiated when administered during periods of low endogenous somatostatin activity, which has informed research designs using Sermorelin as an acute stimulus compound in GH stimulation tests.
Comparative studies have examined Sermorelin alongside GHRP compounds — particularly GHRP-2, GHRP-6, and Ipamorelin — to characterize the synergistic GH response observed when GHRH receptor and ghrelin receptor pathways are activated simultaneously. These studies have contributed to understanding of how the two convergent pathways regulate GH secretion, and have provided a pharmacological basis for combination research designs.
Sermorelin’s clinical history as a pediatric GH deficiency diagnostic and therapeutic agent provides a foundation for ongoing research in GH deficiency models. Research has examined Sermorelin both as a diagnostic tool — where GH response to Sermorelin administration distinguishes pituitary GH deficiency from GHRH deficiency — and as a therapeutic agent for restoring GH secretory activity.
Preclinical and clinical studies in adult GH deficiency models have documented Sermorelin’s ability to stimulate residual pituitary GH secretion in subjects with partial GH deficiency, with treated groups showing improvements in IGF-1 levels and, in longer-duration studies, measurable changes in body composition. Research comparing the pituitary-stimulating approach of Sermorelin to direct GH administration has examined differences in GH pulse patterns, IGF-1 stability, and feedback regulation between the two approaches.
One of the most active areas of Sermorelin research involves the somatopause — the age-related decline in GH secretion and IGF-1 levels that begins in early adulthood and progresses through later life. Research has examined whether restoration of GHRH stimulation through Sermorelin administration can reverse or attenuate somatopausal changes in body composition, bone density, and metabolic function.
Studies in aging animal models have documented Sermorelin-associated increases in GH pulse amplitude and IGF-1 levels, with downstream effects on body composition including lean mass preservation and fat mass reduction. Research has also examined Sermorelin’s effects on aging-associated changes in sleep architecture, given the well-established relationship between GH secretion and slow-wave sleep.
Of particular research interest is the distinction between the somatotroph-stimulating approach of Sermorelin and the pituitary-bypassing approach of exogenous GH: Sermorelin requires functional pituitary somatotrophs to produce a GH response, making it useful as a probe of residual pituitary secretory capacity in aging studies.
Research examining Sermorelin’s downstream metabolic effects has documented effects on body composition, lipid metabolism, and nitrogen balance consistent with GH/IGF-1 axis activation. Studies in adult subjects have reported increases in lean body mass and decreases in fat mass over 6-12 month treatment periods, with the magnitude of effect generally correlated with the degree of baseline GH axis insufficiency.
Metabolic research has examined Sermorelin’s effects on insulin-like growth factor binding proteins (IGFBPs) — the regulatory proteins that modulate IGF-1 bioavailability and tissue distribution. Studies have documented changes in IGFBP-3 levels in Sermorelin-treated subjects, with implications for understanding the tissue-specific distribution of IGF-1 bioactivity in GH axis restoration protocols.
Growing research interest has focused on GHRH’s roles in the central nervous system beyond its classical pituitary function. GHRHR is expressed in multiple brain regions, and GH/IGF-1 signaling has well-documented effects on neuronal survival, myelination, and cognitive function. Research has examined whether Sermorelin-driven GH axis activation produces measurable effects on cognitive parameters in aging models.
Preclinical studies have examined Sermorelin in rodent models of neurological aging, documenting effects on spatial memory performance, hippocampal IGF-1 levels, and markers of neuronal health in treated versus control groups. These findings have motivated research interest in the GHRH-GH-IGF-1 axis as a potential target for interventions aimed at maintaining cognitive function with advancing age.
Understanding Sermorelin’s research applications requires appreciation of the GHRH-GH-IGF-1 axis — the layered endocrine system through which hypothalamic GHRH drives pituitary GH secretion, which in turn drives hepatic IGF-1 production and tissue-level IGF-1 signaling.
Sermorelin activates this axis at the first step — hypothalamic-pituitary signal transduction — rather than at the GH receptor or IGF-1 receptor levels. This upstream point of intervention preserves the entire downstream signaling apparatus, including the regulatory feedback loops through which IGF-1 suppresses further GHRH and GH secretion. The preservation of these feedback mechanisms means that Sermorelin-driven GH elevation is self-limiting: IGF-1 accumulation suppresses GHRHR sensitivity, preventing the sustained supraphysiological GH levels that characterize exogenous GH administration.
This self-regulatory property is considered a research advantage by investigators examining physiological GH secretion restoration — Sermorelin cannot drive GH levels above what the pituitary’s secretory capacity and the axis’s own feedback mechanisms allow, making it safer to study in long-duration protocols than direct GH administration. It is also a limitation in research designs that require precisely titrated supraphysiological GH levels, for which direct GH administration remains the standard approach.
Sermorelin, as a 29-amino acid peptide, requires careful storage and handling to maintain activity. Its relatively modest molecular size compared to larger peptides provides reasonable solution stability under appropriate conditions, but proteolytic susceptibility in biological matrices must be considered in assay design.
Short plasma half-life: Sermorelin’s 10-20 minute plasma half-life means that research designs relying on sustained GHRH stimulation must account for rapid clearance. Continuous infusion protocols or repeated administration designs are required for studies examining sustained GH axis activation with Sermorelin, in contrast to the single-administration paradigms practical with longer-acting analogues such as CJC-1295 DAC.
Somatostatin interference: Sermorelin’s GH-stimulating effect is reduced when endogenous somatostatin tone is high. Research designs examining GH pulse response to Sermorelin should standardize administration timing relative to circadian somatostatin patterns, or include somatostatin measurement as a covariate in GH response analyses.
Pituitary functional status: Unlike direct GH administration, Sermorelin requires functional anterior pituitary somatotrophs to produce a GH response. Research in models where pituitary function is impaired or pharmacologically suppressed will show attenuated Sermorelin responses — a confounding variable that must be considered when interpreting GH stimulation data.
Freeze-thaw sensitivity: Reconstituted Sermorelin should be aliquoted to avoid repeated freeze-thaw cycles. Prepare single-use aliquots where experimental designs permit, and store reconstituted solutions at 4°C for no longer than 30 days.
Official Peptides supplies research-grade Sermorelin acetate at >99% purity verified by HPLC and confirmed by mass spectrometry. Each batch is accompanied by a certificate of analysis from an independent third-party laboratory. We maintain consistent US-based inventory with cold pack shipping and same-day dispatch on qualifying orders.
For research programs requiring Sermorelin alongside complementary GHRH pathway compounds — including Ipamorelin, CJC-1295 No DAC, or CJC-1295 DAC — Official Peptides maintains full inventory of the complete growth hormone secretagogue research catalog.
All content is provided for research reference purposes only. For in vitro laboratory research use only.